RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to investigate if RAD001 is an effective treatment for
pancreatic cancer that has spread and not responded to treatment. Experiments have shown that
RAD001 can prevent cells from multiplying. RAD002 has also been tested in laboratory
experiments imitating cancer conditions and the results have been promising.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Massachusetts General Hospital Novartis